CurrentBlue Cross Blue Shield - MassachusettsPolicy 455

Adoptive Immunotherapy (Cellular Immunotherapy) for Solid Tumors and Other Non‑Hematologic Indications

This policy governs coverage and medical necessity considerations for adoptive immunotherapy techniques (including tumor‑infiltrating lymphocytes, cytotoxic T lymphocytes, cytokine‑induced killer cells, dendritic cell infusions, and related procedures) for cancers and indications other than the specific CAR T‑cell therapies and melanoma lymphocyte products covered in other policies. It applies to Commercial and Medicare members of Blue Cross Blue Shield Massachusetts as described.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyAdoptive Immunotherapy (Cellular Immunotherapy) for Solid Tumors and Other Non‑Hematologic Indications

Policy CodePolicy 455

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization when the procedure is performed inpatient; report services using up-to-date procedure and diagnosis codes and note that HCPCS S2107 is listed as investigational.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1Investigational HCPCS (S2107)

precert requiredInpatient authorization

not coveredOutpatient coverage

insufficientEvidence conclusion

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Policy Stance

Investigational classification / Not medically necessary

Covered when ALL of the following apply (policy-level summary):

Policy stance: All adoptive immunotherapy techniques intended to enhance immunity against cancers are considered investigational for the indications included (examples: Epstein-Barr virus–associated cancers, Cytomegalovirus-associated cancers, nasopharyngeal cancer, renal cell carcinoma, gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small-cell lung cancer, melanoma, glioblastoma multiforme, medullary thyroid cancer, pancreatic cancer, and cancers treated with autologous peripheral T lymphocytes containing tumor antigen–specific T-cell receptors).

Statement of investigational classification in policy.

Investigational / Insufficient Evidence determinations

Summary coverage stance based on available evidence for each therapy and indication:

TILs — EBV-associated nasopharyngeal carcinoma: Randomized trial of adjuvant tumor-infiltrating lymphocytes (TILs) following standard chemoradiation found no difference in progression-free survival or other clinical outcomes compared with standard chemoradiation alone; evidence is insufficient to determine an improvement in net health outcome.

Evidence summary: RCT showed no benefit.

Cytotoxic T lymphocytes (CTL) — EBV- and CMV-associated cancers: Evidence includes 1 RCT (EBV-associated) showing no significant difference in OS or PFS and small prospective series; insufficient evidence to establish efficacy; larger multicenter randomized trials with appropriate controls are needed.

Evidence insufficient; RCT negative for EBV-associated nasopharyngeal carcinoma.

Cytokine-induced killer (CIK) cells — nasopharyngeal carcinoma, RCC, gastric, CRC, HCC, NSCLC: Evidence across indications includes single RCTs, multiple RCTs, and meta-analyses with heterogeneous methods and non‑U.S. settings; some studies reported favorable effects on survival or response in specific comparisons, but limitations (small sample sizes, nonstandard comparators, heterogeneity) preclude definitive conclusions; evidence is insufficient to determine improvement in net health outcome.

CIK evidence heterogeneous; larger well-conducted RCTs needed.

Dendritic cell (DC) vaccines — glioblastoma, NSCLC, pancreatic cancer, medullary thyroid cancer: For glioblastoma, meta-analyses and an RCT/phase III externally controlled study report variable results with some OS advantages relying on non‑propensity‑matched external controls; for NSCLC, RCTs, a cohort study, and a meta-analysis report some benefits but are limited by non‑U.S. settings and nonstandard control arms; for pancreatic cancer and MTC evidence is limited to small noncomparative studies; overall evidence is insufficient to establish efficacy.

DC vaccine evidence limited and heterogeneous; causal inference limited.

Autologous peripheral T lymphocytes with tumor antigen-specific TCRs — various cancers: Multiple small observational studies in melanoma, lymphomas, prostate tumors, neuroblastoma, and other tumors provide noncomparative data with small sample sizes; evidence is insufficient to determine net health benefit and larger randomized trials are required.

Observational, noncomparative studies only; insufficient evidence.

Outpatient adoptive immunotherapy services are not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM members. Claims for outpatient procedures described in this policy may be denied in accordance with product coverage terms.

Adoptive immunotherapy techniques intended to enhance immunity against cancers are considered investigational for the indications included in this policy (and not limited to those listed), including but not limited to Epstein–Barr virus– and cytomegalovirus‑associated cancers, nasopharyngeal cancer, renal cell carcinoma, gastric cancer, colorectal cancer, hepatocellular carcinoma, non‑small‑cell lung cancer, melanoma, glioblastoma multiforme, medullary thyroid cancer, pancreatic cancer, and therapies using autologous peripheral T lymphocytes containing tumor antigen‑specific T‑cell receptors.

There are no additional explicit exclusions in this section beyond the investigational determinations described; the policy does not list other standalone exclusionary categories for the therapies discussed.

Consistent with the evidence review and coding guidance, adoptive immunotherapy techniques reviewed in this policy are designated investigational / not medically necessary for the indications discussed. The policy lists HCPCS code S2107 as investigational and inclusion of a code does not imply coverage.

Specific adoptive immunotherapy interventions evaluated (for which evidence was judged insufficient to establish improvement in net health outcomes) include: tumor‑infiltrating lymphocytes (TILs), dendritic cell (DC) vaccines, autologous peripheral T lymphocytes with tumor antigen‑specific T‑cell receptors (TCRs), and cytokine‑induced killer / DC‑CIK approaches. Across indications, available studies are primarily small, noncomparative, or rely on non‑standard external controls, and therefore do not provide adequate evidence of benefit.

Coding and Billing

Investigational HCPCS CodesHCPCSNot Covered

S2107

Adoptive immunotherapy, i.e., development of specific anti-tumor reactivity (e.g., tumor infiltrating lymphocyte therapy) per course of treatment

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required for Inpatient Services

Prior authorization (precertification) is required for all inpatient services described in this policy. Lack of required precertification for inpatient procedures may lead to claim denial.

Precertification/preauthorization is required for inpatient services.
Failure to precertify inpatient services may result in denial.

Denial Risk

Outpatient Noncoverage Triggers Denial

For outpatient settings, adoptive immunotherapy services are not covered for Commercial products (Managed Care HMO/POS, PPO, Indemnity) and Medicare products listed; outpatient claims for these products will be denied as not covered.

Commercial Managed Care (HMO and POS), Outpatient = not a covered service.

Background and Context

Adoptive immunotherapy employs harvested immune cells that are expanded, selected, or modified ex vivo and then infused to produce an antitumor immune response. These approaches may use autologous cells (derived from the patient) or allogeneic donor cells, and commonly involve steps such as lymphocyte collection, in vitro propagation/selection, a lymphodepleting preparative regimen, and reinfusion with or without adjunctive cytokine support. The intent is to provide tumor‑directed effector cells to mediate tumor cell killing or stimulate endogenous immune responses.

Definitions and Therapy Descriptions

Adoptive cellular therapy — definition

TermAdoptive cellular therapy

DefinitionThe administration of a patient's own (autologous) or donor (allogeneic) antitumor lymphocytes following a lymphodepleting preparative regimen.

Common stepsLymphocyte harvesting, in vitro propagation/selection of tumor-reactive lymphocytes, host lymphodepletion, and adoptive transfer (transfusion) back into the tumor-bearing host.

Sources of harvested cellsPeripheral blood or tumor biopsy specimens are used as starting material for lymphocyte collection.

Purpose of lymphodepletionPreparative immunosuppressive regimen reduces host lymphocytes to improve engraftment and activity of transferred lymphocytes.

TIL / CTL / CIK definitions

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyAdoptive Immunotherapy (Cellular Immunotherapy) for Solid Tumors and Other Non‑Hematologic Indications

Policy CodePolicy 455

Change TypeNo material change

Effective Date

Next Review Date

SourceLink

On This Page

Commercial PPO and Indemnity, Outpatient = not a covered service.

Medicare HMO Blue SM, Outpatient = not a covered service.

Medicare PPO Blue SM, Outpatient = not a covered service.

Billing Rule

Coding and Investigational HCPCS Guidance

The following HCPCS code is identified as investigational for Commercial and Medicare product lines; report all services using current industry-standard procedure, revenue, and diagnosis codes including modifiers where applicable.

Providers must use up-to-date CPT/HCPCS/ICD and modifiers when billing.
HCPCS S2107 is considered investigational for Commercial and Medicare members (informational).

Step Therapy

No step therapy requirements are specified in this policy for adoptive immunotherapy procedures.

Documentation Required

Documentation Supporting Investigational Determinations

Providers should include clinical history, prior treatments, and pertinent literature or references when submitting documentation to support determinations about investigational status. Documentation should be sufficient to demonstrate medical necessity per contract.

Include patient history and prior lines of therapy.
Provide relevant literature citations or clinical trial identifiers when available.
Ensure documentation aligns with the member's contract benefit limitations.

Denial Risk

Denial Risk for Investigational Adoptive Cell Therapies

Adoptive cell therapies described in this policy (including tumor‑infiltrating lymphocytes, dendritic cell vaccines, and autologous peripheral T lymphocytes/TCR therapies) have insufficient evidence for net health benefit and therefore carry a denial risk; providers should verify coverage and submit prior authorization for inpatient cases where applicable.

Tumor-infiltrating lymphocytes (TIL) — evidence insufficient for clinical benefit (denial risk).
Dendritic cell therapies across indications — evidence insufficient; trial heterogeneity and methodological limitations noted.
Autologous peripheral T lymphocytes/TCR therapies — evidence insufficient; observational data only.

Note

Prior Authorization — Provider Reminder

Operational reminder: prior authorization processes and requirements referenced in this section apply and should be followed; contact the payer's precertification department for product-specific submission requirements and timelines.

Prior authorization rules noted in this section may apply; confirm payer-specific process before service.
Contact Blue Cross Blue Shield of Massachusetts precertification for submission instructions.

TILs (Tumor-infiltrating lymphocytes)Innate lymphocytes harvested from tumor biopsy and expanded in vitro (commonly with IL-2 and anti-CD3); expansion is labor-intensive and successful in ~50% of tumors infiltrated by T cells.

CTLs (Cytotoxic T lymphocytes)Select populations of peripheral T cells propagated in vitro with antigen-presenting dendritic cells pulsed with tumor antigens to yield tumor-antigen–specific cytotoxic T cells.

CIK cells (Cytokine-induced killer cells)Rapidly proliferating antitumor effector cells generated in vitro with cytokine stimulation; reported to have broader tumor-target spectrum and stronger antitumor activity than some other effector cells.

Activation/expansion methodsIn vitro propagation using cytokines (eg, IL-2, IL-7, IL-15), anti-CD3 stimulation, and antigen presentation by dendritic cells; may include selection assays to enrich tumor-reactive clones.

Tumor-infiltrating lymphocytes (TILs)

Core definitionAutologous T cells expanded from a patient’s tumor and reinfused to target tumor cells.

Common expansion methodHarvest TIL from tumor biopsy and expand in vitro with IL-2 and T-cell activators (eg, anti-CD3 antibody); process is labor-intensive and not always successful.

Evaluated indications (examples)Adjuvant therapy for EBV-associated nasopharyngeal carcinoma (RCT showed no PFS benefit); investigated across various solid tumors in small series and trials.

Evidence summaryRandomized trial in EBV-associated nasopharyngeal carcinoma found no difference in PFS or other clinical outcomes versus standard chemoradiation; overall evidence insufficient to conclude net health benefit.

Dendritic cell (DC) vaccines

DefinitionAutologous or derived dendritic cells pulsed with tumor antigens (or transfected with antigen vectors) intended to stimulate antitumor T-cell responses when re-infused into the patient.

MechanismHarvest patient dendritic cells, load with tumor antigen (eg, peptide, lysate, or vector), then re-infuse to present antigen to CD4+ and CD8+ T cells and elicit cytotoxic responses.

Studied tumor typesGlioblastoma multiforme, non–small-cell lung cancer (NSCLC), pancreatic cancer, medullary thyroid cancer (MTC), and others.

Evidence summaryTrials and meta-analyses report heterogeneous results (some OS advantages in externally controlled studies for glioblastoma; limited and noncomparative data in pancreatic cancer and MTC); overall evidence insufficient to establish efficacy.

Autologous peripheral T lymphocytes with tumor antigen-specific TCRs

DefinitionAutologous peripheral T lymphocytes engineered or selected to express tumor antigen–specific T-cell receptors (TCRs) and reinfused to target tumor cells.

MethodsPatient-derived T cells are selected or genetically modified to express TCRs specific to tumor antigens; approaches include gene transfer of tumor-specific TCR sequences.

Evaluated contextsReported in small observational series across melanoma, Hodgkin and non-Hodgkin lymphoma, prostate cancer, neuroblastoma, colorectal cancer, and other tumor types.

Evidence summaryAvailable evidence consists primarily of small, noncomparative observational studies; larger randomized trials with standardized methods are needed to determine net health benefit.